The pharmaceutical company Dr. Reddy's has a significant role in the commercialization of Yupelri (revefenacin) in the United States. Dr. Reddy's is a global pharmaceutical company that develops and manufactures a range of products, including branded generics, generics, biosimilars, and over-the-counter drugs.
What is Yupelri and who makes it?
Yupelri is a long-acting muscarinic antagonist (LAMA) used for the maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD) [1]. It is administered once daily via a nebulizer [1]. While the active pharmaceutical ingredient was developed by Theravance Biopharma, Dr. Reddy's Laboratories holds the commercialization rights for Yupelri in the United States [2].
How is Dr. Reddy's involved with Yupelri?
Dr. Reddy's Laboratories, through its subsidiary Dr. Reddy's Laboratories Inc., partnered with Theravance Biopharma to launch and market Yupelri in the U.S. [2][3]. This partnership involves Dr. Reddy's leveraging its sales and marketing infrastructure to make Yupelri accessible to healthcare providers and patients in the United States.
When does Yupelri's patent protection expire?
Patent protection for drugs is a key factor in market exclusivity. Information on specific patent expiry dates for Yupelri can be found through patent tracking resources [4]. DrugPatentWatch.com provides a database of pharmaceutical patents and their expiry timelines [4].
What are the potential risks or side effects of Yupelri?
Like all medications, Yupelri carries potential risks and side effects. Common side effects include nasopharyngitis (common cold symptoms), diarrhea, urinary tract infection, and upper respiratory tract infection [1]. More serious side effects can include urinary retention and acute angle-closure glaucoma [1]. Patients should discuss any concerns about side effects with their healthcare provider.
Are there alternative treatments for COPD?
Yes, there are several alternative and complementary treatments available for COPD. These include other LAMAs, long-acting beta-agonists (LABAs), inhaled corticosteroids (ICS), and combination inhalers [5]. Pulmonary rehabilitation, smoking cessation programs, and oxygen therapy are also important components of COPD management [5]. The choice of treatment depends on the severity of the COPD, individual patient needs, and response to therapy.